Core Concept: In the wake of COVID-19, decentralized clinical trials move to center stage [Medical Sciences]
In January 2021, New York’s Northwell Health hospital system launched a clinical trial to learn whether the over-the-counter drug famotidine (also known as Pepcid) reduces the severity of COVID-19 in symptomatic patients who do not require hospitalization. The randomized trial began in response to anecdotal reports along with clinical studies... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - November 17, 2021 Category: Science Authors: Marcus A. Banks Tags: Core Concepts, Medical Sciences, Front Matter, Coronavirus Related Source Type: research
Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells
CONCLUSION: These findings revealed a novel role of famotidine in cell pyroptosis in patients with gastric cancer, a comprehensive consideration is needed in treatment of gastric cancer.PMID:34686215 | PMC:PMC8539739 | DOI:10.1186/s40360-021-00533-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - October 23, 2021 Category: Drugs & Pharmacology Authors: Jin Huang Pingsheng Fan Miao Liu Chengtao Weng Gaofei Fan Tengyue Zhang Xiaohong Duan Yang Wu Lili Tang Guohong Yang Yabei Liu Source Type: research
Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro
AbstractProton pump inhibitors (PPIs) have been associated with an increased risk of fragility fractures in pharmaco-epidemiological studies. The mechanism is unclear, but it has been speculated that by neutralising gastric acid, they may reduce intestinal calcium absorption, causing secondary hyperparathyroidism and bone loss. Here we investigated that hypothesis that the skeletal effects of PPI might be mediated by inhibitory effects on the bone-specific phosphatase PHOSPHO1. We found that the all PPIs tested inhibited the activity of PHOSPHO1 with IC50 ranging between 0.73 µM for esomeprazole to 19.27 µM for pantop...
Source: Calcified Tissue International - October 22, 2021 Category: Orthopaedics Source Type: research
Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells
Cell pyroptosis has been characterized by cell swelling and pro-inflammatory factors release to aggravate inflammatory reaction., such as interlukin-1 beta (IL-1 β) and interlukin18 (IL-18). However, the functi... (Source: BMC Clinical Pharmacology)
Source: BMC Clinical Pharmacology - October 22, 2021 Category: Drugs & Pharmacology Authors: Jin Huang, Pingsheng Fan, Miao Liu, Chengtao Weng, Gaofei Fan, Tengyue Zhang, Xiaohong Duan, Yang Wu, Lili Tang, Guohong Yang and Yabei Liu Tags: Research Source Type: research
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis
ConclusionFamotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - October 13, 2021 Category: Gastroenterology Source Type: research
More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
(Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - October 13, 2021 Category: Gastroenterology Source Type: research
Famotidine Possible Cutaneous Rash in Covid-19 Patients: An Adverse Effect Case Series
Conclusion: These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.PMID:34636306 | DOI:10.2174/1574886316666211005102711 (Source: Current Drug Safety)
Source: Current Drug Safety - October 12, 2021 Category: Drugs & Pharmacology Authors: Mohammadreza Salehi Hossein Khalili Zahra Jahani Mehrnaz Rasoolinegad Fereshte Ghiasvanad Source Type: research
Famotidine Possible Cutaneous Rash in Covid-19 Patients: An Adverse Effect Case Series
Conclusion: These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.PMID:34636306 | DOI:10.2174/1574886316666211005102711 (Source: Current Drug Safety)
Source: Current Drug Safety - October 12, 2021 Category: Drugs & Pharmacology Authors: Mohammadreza Salehi Hossein Khalili Zahra Jahani Mehrnaz Rasoolinegad Fereshte Ghiasvanad Source Type: research
Combined effect of oral famotidine and cimetidine on the survival of lethally irradiated mice: An in vivo study
Conclusions: Results imply that the combined regimen of famotidine + cimetidine in radioprotection had no significant higher DRF than with regimens including each of them separately. In addition, we did not find a synergic effect of combined oral famotidine and cimetidine on irradiated mice. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - September 14, 2021 Category: Cancer & Oncology Authors: Karim Afsar dizaj Ali Shabestani Monfared Hossein Mozdarani Ali Naeiji Abolfazl Razzaghdoust Karimollah Hajian-tilaki Bahareh Aboufazeli Fatemeh Niksirat Sajad Borzoueisileh Source Type: research
Recent advances in management of COVID-19: A review
In this study, selected novel pharmacological agents for the possible treatment of COVID-19 will be discussed. Point of discussion will cover mechanism of action, supporting evidence for safety and efficacy and reached stage in development. Drugs were classified into three classes according to the phase of viral life cycle they target. Phase I, the early infective phase, relies on supportive care and symptomatic treatment as needed. In phase II, the pulmonary phase, treatment aims at inhibiting viral entry or replication. Drugs used during this phase are famotidine, monoclonal antibodies, nanobodies, ivermectin, remdesivir...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 6, 2021 Category: Drugs & Pharmacology Authors: Soraya Mouffak Qamar Shubbar Ekram Saleh Raafat El-Awady Source Type: research
Omeprazole-induced Visual Hallucinations: A Case Report
In this report, we present a case of visual hallucinations secondary to PPI usage and propose possible mechanisms. In this case, a 65-year-old man with no psychiatric history developed acute visual hallucinations following initiation of omeprazole, in the absence of delusions, paranoia, and other psychotic symptoms. The visual hallucinations began after the patient started treatment with omeprazole and resolved almost immediately upon discontinuation of omeprazole. To treat symptoms of gastroesophageal reflux disease, omeprazole was replaced with famotidine, and the visual hallucinations did not recur after the omeprazole ...
Source: Journal of Psychiatric Practice - September 1, 2021 Category: Psychiatry Tags: Clinical Case Discussions Source Type: research
